Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer.
Cian M McCruddenJohn W McBrideJoanne McCaffreyEmma M McErleanNicholas J DunneVicky L KettJonathan A CoulterTracy RobsonHelen O McCarthyPublished in: Cancer nanotechnology (2018)
These studies further validate RALA as a genetic cargo delivery vehicle and iNOS as a potent therapy for the treatment of cancer.